{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:14:04Z","timestamp":1758399244194,"version":"3.37.3"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chronic lymphocytic leukemia (CLL) and other non-Hodgkin\u2019s lymphomas (NHLs) lead to broad immunosuppression, conferring a greater risk for morbidity and mortality from SARS-CoV-2. Our study analyzed antibody (Ab) seropositivity from SARS-CoV-2 vaccination in patients with these cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In the final analysis, 240 patients were involved, and seropositivity was defined as a positive total or spike protein Ab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seropositivity was 50% in CLL, 68% in WM, and 70% in the remaining NHLs. Moderna vaccination led to higher seropositivity compared to Pfizer vaccination across all cancers (64% vs. 49%; P = .022) and specifically CLL patients (59% vs. 43%; P = .029). This difference was not explainable by differences in treatment status or prior anti-CD20 monoclonal Ab therapy. In CLL patients, current or prior cancer therapy led to lower seropositivity compared to treatment-na\u00efve patients (36% vs. 68%; P = .000019). CLL patients treated with Bruton\u2019s tyrosine kinase (BTK) inhibitors had better seropositivity after receiving the Moderna vaccination compared to Pfizer (50% vs. 23%; P = .015). Across all cancers, anti-CD20 agents within 1 year led to a lower Ab response compared to greater than one year (13% vs. 40%; P = .022), a difference which persisted after booster vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Antibody response is lower in patients with indolent lymphomas compared to the general population. Lower Ab seropositivity was found in patients with a history of anti-leukemic agent therapy or those immunized with Pfizer vaccine. This data suggests that Moderna vaccination may confer a greater degree of immunity against SARS-CoV-2 in patients with indolent lymphomas.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad121","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T18:29:37Z","timestamp":1683224977000},"page":"e930-e941","source":"Crossref","is-referenced-by-count":2,"title":["Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-5395","authenticated-orcid":false,"given":"Peter G","family":"Doukas","sequence":"first","affiliation":[{"name":"Department of Medicine, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederique","family":"St. Pierre","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlei","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Biostatistics, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Boyer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Nieves","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-9671","authenticated-orcid":false,"given":"Michael G","family":"Ison","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases and Organ Transplantation, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane N","family":"Winter","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo I","family":"Gordon","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-5486","authenticated-orcid":false,"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Northwestern Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"10091","key":"2023100311180992300_CIT0001","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-\u00adHodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"2023100311180992300_CIT0002","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.26082","article-title":"Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management","volume":"96","author":"Gertz","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2023100311180992300_CIT0003","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/ijms21051825","article-title":"Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions","volume":"21","author":"Arruga","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2023100311180992300_CIT0004","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev"},{"issue":"5","key":"2023100311180992300_CIT0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023100311180992300_CIT0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.6004\/jnccn.2015.0045","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 1.2015","volume":"13","author":"Zelenetz","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2023100311180992300_CIT0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-005-0015-8","article-title":"Immune defects in patients with chronic lymphocytic leukemia","volume":"55","author":"Ravandi","year":"2006","journal-title":"Cancer Immunol Immunother."},{"issue":"1","key":"2023100311180992300_CIT0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2023100311180992300_CIT0009","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"2023100311180992300_CIT0010","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2023100311180992300_CIT0011","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/s41375-020-0941-7","article-title":"COVID-19 among fit patients with CLL treated with venetoclax-based combinations","volume":"34","author":"Furstenau","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2023100311180992300_CIT0012","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3390\/cancers14092209","article-title":"Outcomes of cancer patients with COVID-19 in a hospital system in the Chicago Metropolitan Area","volume":"14","author":"Mina","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2023100311180992300_CIT0013","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.ymthe.2021.08.001","article-title":"A comprehensive analysis of the efficacy and safety of COVID-19 vaccines","volume":"29","author":"Cai","year":"2021","journal-title":"Mol Ther"},{"key":"2023100311180992300_CIT0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"2023100311180992300_CIT0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000521229","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia: a serologic and cellular study","volume":"67","author":"Molica","year":"2021","journal-title":"Chemotherapy"},{"issue":"13","key":"2023100311180992300_CIT0016","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative","volume":"40","author":"Song","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023100311180992300_CIT0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/2643-3230.BCD-21-0222","article-title":"CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity","volume":"3","author":"Shree","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"26","key":"2023100311180992300_CIT0018","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.22.00088","article-title":"Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"40","author":"Chang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023100311180992300_CIT0019","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s43018-022-00364-3","article-title":"Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study","volume":"3","author":"Lim","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"2023100311180992300_CIT0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2021.5437","article-title":"Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations","volume":"8","author":"Mair","year":"2022","journal-title":"JAMA Oncol"},{"issue":"16","key":"2023100311180992300_CIT0021","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell \u00adnon-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"2023100311180992300_CIT0022","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2023100311180992300_CIT0023","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0953-6205(01)00149-2","article-title":"Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients","volume":"12","author":"van der Velden","year":"2001","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2023100311180992300_CIT0024","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000204315","article-title":"Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients","volume":"91","author":"Gribabis","year":"1994","journal-title":"Acta Haematol"},{"issue":"6","key":"2023100311180992300_CIT0025","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/21645515.2018.1436424","article-title":"Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia","volume":"14","author":"Lindstrom","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"2023100311180992300_CIT0026","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.vaccine.2007.10.053","article-title":"Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia","volume":"26","author":"Sinisalo","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"2023100311180992300_CIT0027","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10875-007-9073-3","article-title":"Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma","volume":"27","author":"Centkowski","year":"2007","journal-title":"J Clin Immunol"},{"issue":"23","key":"2023100311180992300_CIT0028","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023100311180992300_CIT0029","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"issue":"19","key":"2023100311180992300_CIT0030","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"2023100311180992300_CIT0031","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"2023100311180992300_CIT0032","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100311180992300_CIT0033"},{"key":"2023100311180992300_CIT0034"},{"issue":"6","key":"2023100311180992300_CIT0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100311180992300_CIT0036","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152930","article-title":"COVID vaccine antibody responses in patients with hematologic malignancies in a myeloid enriched cohort: a better antibody response in patients with myeloid malignancies than B-cell malignancies","author":"Goksu","year":"2021"},{"issue":"7","key":"2023100311180992300_CIT0037","article-title":"Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"key":"2023100311180992300_CIT0038","doi-asserted-by":"crossref","first-page":"103705","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"2023100311180992300_CIT0039","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146832","article-title":"Antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in patients with myeloid and lymphoid neoplasms","author":"Rotterdam","year":"2021"},{"issue":"2","key":"2023100311180992300_CIT0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"2023100311180992300_CIT0041","doi-asserted-by":"crossref","first-page":"e0034121","DOI":"10.1128\/Spectrum.00341-21","article-title":"Differential antibody response to mRNA COVID-19 vaccines in healthy subjects","volume":"9","author":"Wheeler","year":"2021","journal-title":"Microbiol Spectr"},{"issue":"3","key":"2023100311180992300_CIT0042","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"2023100311180992300_CIT0043","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023100311180992300_CIT0044","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150298","article-title":"A third anti-Sars-Cov2 mRNA dose does not overcome the pejorative impact of anti-cd20 therapy and\/or low immunoglobulin level in CLL\/lymphoma patients","author":"Chbat","year":"2021"},{"issue":"11","key":"2023100311180992300_CIT0045","doi-asserted-by":"crossref","first-page":"e043560e043560","DOI":"10.1136\/bmjopen-2020-043560","article-title":"COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data","volume":"10","author":"Cao","year":"2020","journal-title":"BMJ Open"},{"key":"2023100311180992300_CIT0046","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijid.2021.12.357","article-title":"Decreased severity of disease during the first global omicron variant COVID-19 outbreak in a large hospital in Tshwane, South Africa","volume":"116","author":"Abdullah","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"6","key":"2023100311180992300_CIT0047","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e930\/51821310\/oyad121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e930\/51821310\/oyad121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:24:56Z","timestamp":1696332296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/10\/e930\/7152422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5,4]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad121","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,5,4]]}}}